Skip to content

Is a routine upper GI contrast study required for every patient after an oesophageal anastomosis?

Study to assess the requirement of a routine upper GI contrast study post-operatively in patients undergoing an oesophageal anastomosis.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/02/006654
Enrollment
150
Registered
2016-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Esophageal Cancer and gastric cancer Health Condition 2: K318- Other specified diseases of stomach and duodenum

Interventions

Intervention1: An upper GI contrast study with thin Barium or gastrograffin will be done on post operative day 5-7 in group A.: Upper GI contrast study will be done with thin barium or gastrograffin b

Sponsors

Christian Medical College Vellore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients undergoing oesophageal anastomosis(hand sewn or stapled, McKeownâ??s Esophagectomy, Ivor Lewis Esophagectomy, Total Gastrectomy, colon bypass procedures or stomach pull through for corrosive strictures, Patients undergoing an oesophageal anastomosis and other surgeries concurrently(Ex: Cholecystectomy, Splenectomy etc

Exclusion criteria

Exclusion criteria: Patients refusing to participate in the study, pregnant ladies.

Design outcomes

Primary

MeasureTime frame
To assess the delay in starting oral feeds between two groups. To compare readmission rates / re-surgery rates between both groups. To compare duration of post-operative hospital stay between the groups.Timepoint: Outcomes will be assessed till 30th post operative day. To compare readmission rates / re-surgery rates between both groups. To compare duration of post-operative hospital stay between the groups.

Secondary

MeasureTime frame
To evaluate the overall morbidity and 30 day mortality in the two groups.Timepoint: To evaluate the overall morbidity and 30 day mortality in the two groups.

Countries

India

Contacts

Public ContactDr Niveditha Shama V

Christian Medical College, Vellore

inians@cmcvellore.ac.in918870443348

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026